Keyword: AbbVie

With impressive new survival data in hand, Bristol-Myers Squibb and AbbVie could land a new indication for Empliciti.

Some investors supported resolutions asking for more info about the link between drug prices and executive pay.

Endo moved to resolve "all known" testosterone drug lawsuits it faced. The company last year set aside $200 million for the litigation.

AbbVie and Roche just nabbed an FDA approval that spares relapsed leukemia patients chemotherapy—and could be key to $3B in peak sales.

FDA inspectors found that AbbVie didn’t include historical death complaints for the same lot in its search system for its all-too-important drug Humira.

Blockbusters Humira and Keytruda will lead 2024 sales, according to an EvaluatePharma report, joined by new Sanofi launch Dupixent.

Pharma authorized tens of billions of dollars' worth of share buybacks before or shortly after tax reform, and that irked an industry veteran.

AbbVie's Humira held on to its ad spending crown yet again in May, but Sunovion's Latuda jumped up to knock Pfizer's Lyrica out of second place.

Sanofi's net prices fell 8.4% last year, the drugmaker reported in an update to its pricing policies.

Gilead's Epclusa Chinese nod comes just a few weeks after Merck’s Zepatier, and AbbVie's Mavyret is close behind.